Rhythm Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Rhythm Pharmaceuticals's earnings have been declining at an average annual rate of -16.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 80.7% per year.
Key information
-16.5%
Earnings growth rate
-4.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 80.7% |
Return on equity | -144.5% |
Net Margin | -256.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Jun 12Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Revenue & Expenses Breakdown
How Rhythm Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 102 | -261 | 134 | 222 |
31 Mar 24 | 92 | -274 | 127 | 226 |
31 Dec 23 | 77 | -185 | 118 | 135 |
30 Sep 23 | 62 | -186 | 111 | 129 |
30 Jun 23 | 44 | -182 | 103 | 116 |
31 Mar 23 | 34 | -181 | 95 | 114 |
31 Dec 22 | 24 | -181 | 92 | 109 |
30 Sep 22 | 17 | -181 | 87 | 117 |
30 Jun 22 | 13 | -176 | 82 | 123 |
31 Mar 22 | 5 | -166 | 75 | 117 |
31 Dec 21 | 3 | -70 | 68 | 104 |
30 Sep 21 | 1 | -62 | 61 | 95 |
30 Jun 21 | 0 | -60 | 54 | 90 |
31 Mar 21 | 0 | -56 | 48 | 88 |
31 Dec 20 | 0 | -134 | 46 | 90 |
30 Sep 20 | 0 | -132 | 42 | 93 |
30 Jun 20 | 0 | -134 | 42 | 97 |
31 Mar 20 | 0 | -146 | 42 | 109 |
31 Dec 19 | 0 | -141 | 37 | 109 |
30 Sep 19 | 0 | -133 | 36 | 103 |
30 Jun 19 | 0 | -115 | 34 | 88 |
31 Mar 19 | 0 | -87 | 31 | 61 |
31 Dec 18 | 0 | -74 | 28 | 50 |
30 Sep 18 | 0 | -59 | 24 | 38 |
30 Jun 18 | 0 | -53 | 18 | 33 |
31 Mar 18 | 0 | -47 | 13 | 30 |
31 Dec 17 | 0 | -38 | 10 | 23 |
30 Sep 17 | 0 | -36 | 8 | 22 |
30 Jun 17 | 0 | -32 | 7 | 21 |
31 Mar 17 | 0 | -30 | 6 | 21 |
31 Dec 16 | 0 | -29 | 6 | 20 |
30 Sep 16 | 0 | -27 | 6 | 18 |
30 Jun 16 | 0 | -23 | 6 | 14 |
31 Mar 16 | 0 | -17 | 5 | 10 |
31 Dec 15 | 0 | -12 | 3 | 7 |
30 Sep 15 | 0 | -6 | 2 | 4 |
30 Jun 15 | 0 | -3 | 1 | 2 |
31 Mar 15 | 0 | -5 | 1 | 4 |
31 Dec 14 | 0 | -6 | 1 | 5 |
Quality Earnings: RYTM is currently unprofitable.
Growing Profit Margin: RYTM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RYTM is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare RYTM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: RYTM has a negative Return on Equity (-144.53%), as it is currently unprofitable.